Jo�o L. de Quevedo – författare

Neurobiology of Depression: Road to Novel Therapeutics synthesizes the basic neurobiology of major depressive disorder with discussions on the most recent advances in research, including the interacting pathways implicated in the pathophysiology of MDD, omics technologies, genetic approaches, and the development of novel optogenetic approaches that are changing research perspectives and revolutionizing research into depression. These basic foundational understandings on the neurobiology underlying the disorder, along with a comprehensive summary of the most recent advances in research are combined in this book to aid advanced students and researchers in their understanding of MDD.

Depression is one of the most common mental-health disorders caused by a variety of genetic, biological, environmental and psychological factors. Major depressive disorder (MDD) is typically treated with first-line antidepressant agents that primarily target monoamine neurotransmission. However, only approximately one-third of patients with MDD achieve remission following a trial with such an antidepressant. Furthermore, MDD is a heterogeneous phenotype, and new frameworks, such as the NIMH Research Domain Criteria (RDoC) may provide a more accurate, biologically based comprehension of the symptomatic heterogeneity of this devastating illness.

Recent advances in pharmacology and brain stimulation have led to the development of novel treatments for psychiatric disorders. These new advances have led to the development of a new subspecialty, Interventional Psychiatry.

Interventional Psychiatry: Road to Novel Therapeutics reviews all specialized treatments including device-based interventions such as electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), and deep brain stimulation (DBS). This book discusses the procedure-based pharmacologic interventions including ketamine infusion therapy and psychedelic therapies. Internationally contributed, this book outlines the state of the field, as well as implications for training and the role of the interventional psychiatrist in treatment teams.